An interventional study of Survey in Esophageal Cancer and Gastric Cancer, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by KU Leuven · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Esophageal Neoplasms with a site in Belgium — 17 open to participants now, 22 under way, 5 of them phase 3. Esophageal Neoplasms · Belgium.
Among the 41 studies in Esophageal Neoplasms with a site in Belgium, this one has the largest planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 6 of the 21 other live ones, and was the 36th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →17 of the 41 studies in Esophageal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Australia and 21 more countries
Ages 18+
University Hospital, Antwerp · Sites in Belgium, Denmark, France and 3 more countries
Ages 18+
KU Leuven · Sites in Belgium
Ages 18+
Radboud University Medical Center · Sites in Belgium, Netherlands
Ages 18+
KU Leuven · Sites in Belgium
Ages 18–100 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 7
First in 2002; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,200 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 198 across the 32 interventional studies, 787 across the 8 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 3 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Esophageal Neoplasms with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05688176University Hospital, GhentBarrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers | 2027-01-31 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Esophageal Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
The main question it aims to answer are:
Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who will complete a survey investigating their preference for diagnosis and assessment of gastro-esophageal cancer
Other: Survey
Discrete choice survey
The rate of contribution of diagnostic features to the preference of participants
A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants
Time frame: 2 years
The percentage differences in preference of participants between geographical regions
Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test
Time frame: 2 years
Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio
Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.
Time frame: 2 years
Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs
Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.
Time frame: 2 years
Plan to share: Yes — Data will be made available upon reasonable request with the principal investigator
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.
Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 24 months is below that.
Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.